Tanja Obradovic: The landscape of targeting KRAS mutations just got busier

Tanja Obradovic shared on LinkedIn:          .

“The landscape of KRAS mutations targeting landscape just got busier with announcement by GenFleet Therapeutics of receiving IND approval from China’s NMPA for GFH375, an oral KRAS G12D inhibitor and starting in a Phase I/II trial in relapsed refractory advanced solid tumor patients with KRAS G12D mutation with plans to evaluate RP2D in patients with high prevalence of G12D mutation – pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (proceed to the article).

China-based Biotech is starting clinical GFH375 program in collaboration with US-based Verastem Oncology on top of very rich pipeline driven by collaborations with both China and ex-China partners. Interesting to point that this news comes very soon after posting outstanding results for the KRAS G12C mutation inhibitor Fulzerasib in the 1st line for advanced KRAS G12C-mutated NSCLC patients.

Considering that GFH375 will be evaluated in PhI/II placed in approximately 40 centers in China results may come soon so interesting to see where this novel compound will land in terms of safety and efficacy profile considering busy field recently (proceed to the article).

Also, it is an increasingly clear trend of China and in general Asia-Pacific region becoming early clinical development engine that is supporting very strong preclinical innovation in oncology.”

Source: Tanja Obradovic/LinkedIn

Tanja Obradovic is the Vice President of Oncology Scientific Affairs at ICON PLCh. She has over 20 years of clinical research experience and has led major pharmaceutical companies for 13 years. Her research focuses on small molecules, antibodies, cell and gene therapy, and major immunotherapy of PD1 inhibitors.